Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

ASCO 2020: Results of a phase III study comparing pembrolizumab with brentuximab vedotin for treatment of relapsed Hodgkin lymphoma.